NASDAQ · STLN
Starling Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for STLN: Nov 05, 2026
Starling Oncology, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.14.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Dec 2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Aug 6, 7:10 PM EDTThe Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue EstimatesSTARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 15, 3:50 AM EDTBiotech Stocks Hit 52-Week Highs – TOI, IKT, ANRO, ELV, PRVA(RTTNews) – These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business ventures.
- Zacks · Jul 7, 1:18 PM EDTBest Cheap Stocks Under $10 to Buy Now in JulyOne area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
- Zacks · Jun 29, 10:30 AM EDTThe Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Jun 9, 9:55 AM EDTHow Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- MarketBeat · May 9, 1:06 AM EDTOncology Institute Q1 Earnings Call HighlightsOncology Institute (NASDAQ:TOI) reported a strong start to 2026, with first-quarter revenue rising 41% year over year as the company expanded value-based care arrangements and posted record specialty pharmacy performance. Chief Executive Officer Dan Virnich said the quarter was
- The Motley Fool · May 8, 1:00 PM EDTTOI Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 7, 7:05 PM EDTThe Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue EstimatesThe Oncology Institute (TOI) delivered earnings and revenue surprises of +71.43% and +1.54%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 5, 7:25 AM EDTPediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass EstimatesPediatrix Medical Group (MD) delivered earnings and revenue surprises of +19.73% and +1.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 30, 6:25 PM EDTEnsign Group (ENSG) Q1 Earnings Surpass EstimatesEnsign Group (ENSG) delivered earnings and revenue surprises of +3.35% and -0.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Mar 17, 3:58 PM EDTOncology Institute (TOI) Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 13, 9:02 AM EDTThe Oncology Institute Rises On Strong Q4 Results, Eyes 2026 Profitability(RTTNews) – Shares of The Oncology Institute, Inc. (TOI) are up in the pre-market by 17% following the company's announcement of the fourth quarter and full-year 2025 financial results, which showed significant revenue growth and narrowing losses.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Starling Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.